Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

(Moderate)

(Very Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Argus Feb 17 session

-1.66% close to close Open Argus

Details

News Market Reaction – RARE

On Feb 17, the first trading day after this news, RARE closed 1.66% below the previous close.

Data tracked by StockTitan Argus for the Feb 17 session.

Key Figures

Class period start: August 3, 2023 Class period end: December 26, 2025 Share price pre-drop: $34.19 +5 more

Class period start: August 3, 2023; Alleged securities fraud class period beginning
Class period end: December 26, 2025; Alleged securities fraud class period ending
Share price pre-drop: $34.19; Closing price on December 26, 2025 before UX143 disclosure reaction window
Share price post-drop: $19.72; Closing price on December 29, 2025 after UX143 trial results
Three-day decline: 42%; Share price drop after UX143 Phase 3 Orbit and Cosmic results
Lead plaintiff deadline: April 6, 2026; Deadline to seek appointment as lead plaintiff in class action
Toll-free contact: 1-877-515-1850; Phone number for Kahn Swick & Foti regarding the lawsuit
Phase 3 designation: Phase 3; Orbit and Cosmic studies for setrusumab (UX143) in osteogenesis imperfecta

Historical Context

5 past events · Latest: Feb 12

5 events

Feb 12
Earnings and guidance

24h Move

-1.6%

Reported 2025 revenue growth, large net loss, and restructuring with 10% workforce cut.
Feb 05
Earnings call notice

24h Move

+3.8%

Announced timing and access details for Q4 and full‑year 2025 results call.
Feb 03
UX111 long‑term data

24h Move

+0.2%

Released positive longer‑term UX111 data with sustained biomarker and functional benefits.
Jan 30
UX111 BLA resubmission

24h Move

-0.8%

Resubmitted UX111 BLA to FDA with extended follow‑up and safety data under Priority Review.
Jan 23
Inducement equity grant

24h Move

+0.4%

Granted 16,355 RSUs to new non‑executive officers under Nasdaq inducement rule.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

class action, securities fraud, Phase 3, Phase III, +2 more

6 terms

class action regulatory

"notifies investors in Ultragenyx Pharmaceutical Inc. ("Ultragenyx" ) ... of a class action securities lawsuit."

A class action is a lawsuit where a group of people with similar complaints sue a company together instead of each person filing separately; think of it as a neighborhood banding together to take one case to court rather than everyone hiring separate lawyers. Investors care because class actions can lead to large settlements or judgments, damage a company’s reputation, drain cash reserves, and distract management — all of which can reduce a company’s stock value and affect future earnings.

securities fraud regulatory

"investors of Ultragenyx who were adversely affected by alleged securities fraud between August 3, 2023 and December 26, 2025."

Securities fraud is the illegal act of lying to or misleading investors about the true value or prospects of stocks, bonds or other traded financial instruments — for example by making false statements, hiding key facts, trading on secret information, or artificially moving prices. It matters to investors because it can cause sudden losses, distort fair market prices and undermine trust in markets; think of it as someone rigging a scoreboard so others place bets on the wrong team.

View in glossary

Phase 3 medical

"announced the "results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143)"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

Phase III medical

"both its Phase III Orbit and Cosmic studies failed to demonstrate that setrusumab"

A Phase III trial is the late-stage clinical study that tests whether a medical treatment works and is safe in a large group of patients, often comparing it to standard care. Think of it as a final dress rehearsal or full-scale road test before regulators decide on approval; positive or negative results strongly influence a drug maker’s chance to sell the treatment, future revenue, and investment risk.

statistically significant medical

"failed to demonstrate that setrusumab triggered a statistically significant reduction in annualized fracture rates"

"Statistically significant" means that a result or difference observed in data is unlikely to have occurred by chance alone, suggesting there is a real underlying effect. For investors, it indicates that the findings or patterns they see are likely meaningful and not just random noise, helping them make more informed decisions based on reliable information. Think of it as a pattern that is strong enough to stand out clearly from background randomness.

lead plaintiff regulatory

"you have until April 6, 2026 to request that the Court appoint you as lead plaintiff"

The lead plaintiff is the representative investor chosen to speak and act on behalf of a group of shareholders in a securities lawsuit. Think of them as the elected spokesperson for a neighborhood when everyone sues a landlord: they coordinate the legal case, make strategic decisions, and negotiate settlements, so their choices can shape outcomes and any recovery that reaches all affected investors. Investors care because the lead plaintiff’s resources and approach can influence the size and speed of any payout and the costs deducted from it.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

02/13/2026 - 10:19 PM

NEW YORK and NEW ORLEANS, Feb. 13, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NasdaqGS: RARE) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of Ultragenyx who were adversely affected by alleged securities fraud between August 3, 2023 and December 26, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://www.ksfcounsel.com/cases/nasdaqgs-rare/

Ultragenyx investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-rare/ to learn more.

CASE DETAILS: On December 26, 2025, the Company announced the "results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta" disclosing that both its Phase III Orbit and Cosmic studies failed to demonstrate that setrusumab triggered a statistically significant reduction in annualized fracture rates for patients with osteogenesis imperfecta, and, as a result the Company "is evaluating its planned operations and will promptly define and implement significant expense reductions." On this news, the price of Ultragenyx's shares fell approximately 42%, from $34.19 per share on December 26, 2025 to $19.72 per share on December 29, 2025.

The case is Steven Bailey v. Ultragenyx Pharmaceutical Inc., et al., No. 26-cv-01097.

WHAT TO DO? If you invested in Ultragenyx and suffered a loss during the relevant time frame, you have until April 6, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn